Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery

2017 ◽  
pp. 207-220 ◽  
Author(s):  
Klaus Christensen ◽  
Filip Roudnicky ◽  
Christoph Patsch ◽  
Mark Burcin
Keyword(s):  
Drug Discovery ◽  
Assay Development ◽  
Cell Models

Stem Cell Models for Drug Discovery and Toxicology Studies

2013 ◽  
Vol 27 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Wenwei Liu ◽  
Yaguang Deng ◽  
Ying Liu ◽  
Wenrong Gong ◽  
Wenbin Deng
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Cell Models ◽  
Stem Cell Models

Assay development in leishmaniasis drug discovery: a comprehensive review

2021 ◽  
pp. 1-16
Author(s):  
Bilal Zulfiqar ◽  
Vicky. M. Avery
Keyword(s):  
Drug Discovery ◽  
Assay Development ◽  
Comprehensive Review

Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases

2017 ◽  
Vol 177 ◽  
pp. 32-43 ◽  
Author(s):  
Sandy S.C. Hung ◽  
Shahnaz Khan ◽  
Camden Y. Lo ◽  
Alex W. Hewitt ◽  
Raymond C.B. Wong
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Ocular Diseases ◽  
Cell Models ◽  
Induced Pluripotent ◽  
Stem Cell Models

scholarly journals Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery

Molecules ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 1629 ◽  
Author(s):  
Johannes Ottl ◽  
Lukas Leder ◽  
Jonas V. Schaefer ◽  
Christoph E. Dumelin
Keyword(s):  
Drug Discovery ◽  
Cyclic Peptides ◽  
Chemical Space ◽  
Pharmaceutical Research ◽  
Peptide Libraries ◽  
Assay Development ◽  
Low Molecular Weight ◽  
Target Validation ◽  
Lead Finding ◽  
Chemical Matter

The scope of targets investigated in pharmaceutical research is continuously moving into uncharted territory. Consequently, finding suitable chemical matter with current compound collections is proving increasingly difficult. Encoded library technologies enable the rapid exploration of large chemical space for the identification of ligands for such targets. These binders facilitate drug discovery projects both as tools for target validation, structural elucidation and assay development as well as starting points for medicinal chemistry. Novartis internalized two complementing encoded library platforms to accelerate the initiation of its drug discovery programs. For the identification of low-molecular weight ligands, we apply DNA-encoded libraries. In addition, encoded peptide libraries are employed to identify cyclic peptides. This review discusses how we apply these two platforms in our research and why we consider it beneficial to run both pipelines in-house.

Polymer Membrane and Cell Models for Drug Discovery

2012 ◽  
Vol 15 (1) ◽  
pp. 3-14 ◽  
Author(s):  
Chong Shen ◽  
Liang Zhang ◽  
Guoliang Zhang ◽  
Qin Meng
Keyword(s):  
Drug Discovery ◽  
Polymer Membrane ◽  
Cell Models

scholarly journals Capturing the third dimension in drug discovery: Spatially-resolved tools for interrogation of complex 3D cell models

2021 ◽  
pp. 107883
Author(s):  
Daniel Simão ◽  
Catarina M. Gomes ◽  
Paula M. Alves ◽  
Catarina Brito
Keyword(s):  
Drug Discovery ◽  
Cell Models ◽  
The Third ◽  
Spatially Resolved ◽  
Third Dimension

scholarly journals Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery

Pharmaceutics ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 176 ◽  
Author(s):  
Laura Hellinen ◽  
Heidi Hongisto ◽  
Eva Ramsay ◽  
Kai Kaarniranta ◽  
Kati-Sisko Vellonen ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Retinal Pigment ◽  
Cell Monolayer ◽  
Barrier Properties ◽  
Cell Models ◽  
Blood Retinal Barrier ◽  
Rpe Cells ◽  
Cell Monolayers ◽  
Value Range ◽  
Drug Flux

The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are available, there have been no systematic comparisons of their barrier properties with respect to drug permeability. We compared the barrier properties of several RPE secondary cell lines (ARPE19, ARPE19mel, and LEPI) and both primary (hfRPE) and stem-cell derived RPE (hESC-RPE) cells by investigating the permeability of nine drugs (aztreonam, ciprofloxacin, dexamethasone, fluconazole, ganciclovir, ketorolac, methotrexate, voriconazole, and quinidine) across cell monolayers. ARPE19, ARPE19mel, and hfRPE cells displayed a narrow Papp value range, with relatively high permeation rates (5.2–26 × 10−6 cm/s. In contrast, hESC-RPE and LEPI cells efficiently restricted the drug flux, and displayed even lower Papp values than those reported for bovine RPE-choroid, with the range of 0.4–32 cm−6/s (hESC-RPE cells) and 0.4–29 × 10−6 cm/s, (LEPI cells). Therefore, ARPE19, ARPE19mel, and hfRPE cells failed to form a tight barrier, whereas hESC-RPE and LEPI cells restricted the drug flux to a similar extent as bovine RPE-choroid. Therefore, LEPI and hESC-RPE cells are valuable tools in ocular drug discovery.

Zebrafish assay development for cardiovascular disease mechanism and drug discovery

2018 ◽  
Vol 138 ◽  
pp. 126-131 ◽  
Author(s):  
Aaron P. Kithcart ◽  
Calum A. MacRae
Keyword(s):  
Cardiovascular Disease ◽  
Drug Discovery ◽  
Assay Development ◽  
Disease Mechanism

Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development

2011 ◽  
Vol 17 (9) ◽  
pp. 475-484 ◽  
Author(s):  
Richard P. Davis ◽  
Cathelijne W. van den Berg ◽  
Simona Casini ◽  
Stefan R. Braam ◽  
Christine L. Mummery
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
Cardiac Disease ◽  
Pluripotent Stem Cell ◽  
Cell Models ◽  
Drug Discovery And Development ◽  
Stem Cell Models
Sign in / Sign up

Export Citation Format

Share Document